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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease with high prevalence, which 
imposes a substantial public health problem. The heritability of AD is estimated at 60–80% 
forecasting the potential use of genetic biomarkers for risk stratification in the future. Several large 
scale genome-wide association studies using high frequency variants identified 10 loci 
accountable for only a fraction of the estimated heritability. To find the missing heritability, 
systematic assessment of various mutational mechanisms needs to be performed. This copy 
number variation (CNV) genome-wide association study with age at onset (AAO) of AD 
identified 5 CNV regions that may contribute to the heritability of AAO of AD. Two CNV events 
are intragenic causing a deletion in CPNE4. In addition, to further study the mutational load at the 
10 known susceptibility loci, CNVs overlapping with these loci were also catalogued. We 
identified rare small events overlapping CR1 and BIN1 in AD and normal controls with opposite 
CNV dosage. The CR1 events are consistent with previous reports. Larger scale studies with 
deeper genotyping specifically addressing CNV are needed to evaluate the significance of these 
findings.
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Alzheimer’s disease (AD) is a devastating neurodegenerative disorder affecting 
approximately 5.4 million individuals in the US and is the most common cause of dementia 
in North America and Europe [1–3]. Genetic factors play an important role in the 
pathogenesis of AD and contribute to the variance of age at onset (AAO) [4, 5]. Rare 
Mendelian forms of AD have confirmed and elucidated pathways involved in amyloid 
accumulation, but only account for a small percentage of the cases of AD [6]. The 
heritability of late-onset AD (LOAD) is estimated at 60–80%. The population attributable 
risk for the APOE4 allele is calculated at 20–70% in various studies. The recent ADGC 
study calculated the attributable risk for the ten non-APOE4 loci at 35%; however, it was 
felt that it might be an overestimate due to the winner’s curse. Additional loci may 
contribute to the genetic architecture of AD and account for the missing heritability [7]. 
APOE4 has a strong effect on AAO of AD and an additional 4–5 loci may contribute to the 
heritability of AAO [8].
Structural variation of submicroscopic DNA segments (deletions, duplications, and 
inversions) has greatly expanded our understanding of human genetic variation [9]. Copy 
number variations (CNVs) influence gene expression, phenotypic variation, and adaptation 
by altering gene dosage and genome organization [10, 11]. CNVs are often multiallelic and 
have a higher de novo mutation rate, and therefore they are often not adequately tagged by 
single-nucleotide polymorphism (SNPs) [12]. Because of these attributes, CNVs confer a 
novel genetic marker map with different properties representing a supplementary approach 
to SNP association [13]. With the advent of microarray technology allowing genome-wide 
ascertainment of CNVs, disease associations have been reported in various diseases 
including neurological diseases [14].
This study of CNV association with AD AAO was designed to examine the role of low-
frequency variants with intermediate penetrance in the genetic architecture of AD. AAO 
serves as a quantitative endophenotype and the cases-only study design eliminates 
misclassification bias in this common disease with age-dependent penetrance. The 
mutational load architecture is likely to be locus specific, thus the detection of a given 
susceptibility locus will be successful by using the marker map that predominantly 
contributes to the mutational load of that locus, underlining the importance of the systematic 
assessment of all genetic variants. In addition, we catalogued the CNVs overlapping with the 
10 susceptibility loci discovered in the genome-wide association studies (GWAS) to 
evaluate the role of CNVs contributing to the mutational load of these loci.
Published CNV studies in AD [15–19] have focused mostly on large events (>100 kb) to 
achieve high confidence calls and performed the tests of association on these events. We 
previously reported an olfactory receptor cluster association with AAO of AD performing 
the regression analysis on binned numeric logR ratio data without performing segmentation 
[20]. An alternative strategy applied here is to use permissive segmentation only to reduce 
the dataset where events may occur, perform the test of association on the numeric 
segmented data, and validate the CNV calls if a replicated association signal was detected. 
This second approach can detect association signals from smaller events that would have 
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been discarded when performing the high confidence calls and overcomes the need to 
determine exact dosage, which could be problematic at common CNV loci as the reference 
will deviate from the diploid dosage.
METHODS
Subject cohorts
781 subjects were enrolled in the study. Probable AD diagnosis was established by 
NINCDS-ADRDA criteria [21]. The methodology of the Texas Alzheimer Research and 
Care Consortium project has been described in detail elsewhere [22]. Controls were 
recruited at each participating site by the same inclusion criteria, including age over 55 
years, male and female, unrelated to AD subjects, Clinical Dementia Rating (CDR) global 
score 0, normal performance on activities of daily living (ADL), and all information was 
obtained from a surrogate historian. After enrollment all control subjects underwent 
neuropsychological testing including assessment of Global cognitive functioning/status 
(Mini-Mental Status Examination and CDR), Attention (Digit Span and Trails A), Executive 
function (Trails B and Clock Drawing; Texas Card Sorting is optional), Memory (Wechsler 
Memory Scale (WMS) Logical Memory I and WMS Logical Memory II), Language (Boston 
Naming and FAS Verbal Fluency), Premorbid IQ (AMNART), Visuospatial Memory 
(WMS-Visual Reproduction I and II), Psychiatric symptoms (Geriatric Depression Scale; 
Neuropsychiatric Inventory-Questionnaire) and Functional assessment (Lawton-Brody 
ADL: PSMS, IADL). Control subjects showing impairment were excluded from the control 
cohort after consensus review.
Informed consent was obtained from all subjects prior to inclusion. Genomic DNA was 
isolated from whole blood by the Puregene DNA isolation kit (Qiagen) according to the 
manufacturer’s instructions.
AAO phenotyping
AAO was determined with two standardized methods in both cohorts: i) caregiver estimate 
by prompted standard question regarding onset of symptoms and ii) physician estimate of 
duration of illness using a standardized and validated structured interview with landmark 
event to facilitate recall [23].
APOE genotyping
Genotyping was performed according to manufacturer‘s instruction with real-time PCR 
using custom TaqMan probes (Applied Biosystems, Inc) unique for SNPs of rs7412 and 
rs429358 at nucleotides 112 and 158 of the APOE gene, respectively. All amplifications 
were carried out in an ABI 7900HT thermal cycler (Applied Biosystems, Inc). APOE 
genotype was determined from the combination of alleles present at the 112 and 158 
polymorphisms.
CNV genotyping by the genome-wide human SNP array 6.0
Array based genotyping was performed on the Genome-Wide Human SNP Array 6.0 
(Affymetrix) according to the manufacturer’s instructions. QC measures for the Genome-
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Wide Human SNP Array 6.0 (Affymetrix) array included contrast QC (>0.4) and Median of 
the Absolute values of all Pairwise Differences (MAPD) <0.4. Arrays with number of calls 
more than 2SD from the mean were excluded.
Detection of CNV and test of association
We performed principal component analysis using the Eigenstrat method [24] implemented 
in Golden-Helix. The Affymetrix intensity data was corrected for 16 principal components 
as this correction resulted in the QQ plot without evidence of inflation (Supplementary 
Figure 1; available online: http://www.j-alz.com/issues/33/
vol33-2.html#supplementarydata08). The PCA corrected data was segmented by the CNAM 
algorithm implemented in GoldenHelix (Golden-Helix). The univariate method identifies 
rare CNVs by scanning the data subject by subject. In the univariate method, we applied a 
moving window of 20,000 probes: the maximum number of segments per 10,000 markers 
was set at 1 and we set the minimum number of marker per segment at 1 with maximum 
pairwise permuted p-value was set at 0.005, applying 2,000 permutations per pair, to have 
high sensitivity to detect association signals from small events with the expectations that all 
association signal events will be manually reviewed for validation. The multivariate method 
compares all samples at each locus and identifies common CNVs. In the multivariate 
segmentation, we did not apply a moving window and used similar setting as in the 
univariate segmentation (maximum number of segments per 10,000 markers 10, minimum 
number of marker per segment 1, maximum pairwise permuted p-value was set at 0.005, 
applying 2,000 permutations per pair). Both algorithms generate segmentation covariates 
that results in reduction of the dataset to regions of interests where CNV events occur, thus 
limiting the number of tests of association.
For test of association, Cox proportional hazard analysis was performed using the covariates 
from the univariate and multivariate segmentation algorithms. The Cox proportional hazard 
regression script was created in R and the analysis of the corrected log R ratio data as 
predictor and AAO as outcome was performed in R. We used the FDR approach and the 
criteria for significance was set at corrected p-value of <0.05. For the covariates that were 
associated with AAO of AD, the analysis was repeated incorporating gender and APOE 
status (number of APOE alleles as categorical variable) in the proportional hazard model.
We analyzed the NIA-LOAD Familial Study dataset probands deposited in dbGAP (http://
www.ncbi.nlm.nih.gov/gap) for replication of the results. 866 AD subjects were included in 
the analysis from the LOAD dataset selected using the following criteria: probands only, 
Caucasian, non-Hispanic, and AAO data available. The NIA-LOAD Familial Study 
genotyping was performed on the Illumina Human610 Quadv1 B array. The logR ratio was 
calculated in the GenomeStudio (Illumina) software. Candidate locus specific data was 
extracted and Cox porportinal hazard regression was performed on the logR numeric data 
because the candidate regions were inadequately covered for segmentation.
RESULTS
756 samples passed the contrast QC and were adequate for copy number analysis. Forty 
samples failed MAPD cutoff of 0.4 and 143 samples failed due to number of CNV calls 
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more than 2SD of the mean. 573 samples passed QC: 381 AD subjects and 192 normal 
controls. Six AD subjects had missing AAO or APOE genotype, thus 375 AD subjects 
entered the cases-only AAO analysis. Demographics of the 375 subjects are depicted in 
Table 1.
The Cox proportional hazard model identified 14 univariate segments corresponding to 11 
chromosomal regions where the association signal survived multiple testing correction 
depicted in the Manhattan plot (Fig. 1). Five regions remained after manual review of the 
CNV events and the AAO versus segmented logR ratio scatterplots (Table 2). For all of 
these probes/regions, the p-value remained comparable after adding APOE and gender into 
the Cox proportional hazard model (Table 2). The number of events contributing to the 
association signal is depicted in Supplementary Table 1; consistent with the segmentation 
method these events were rare, ranging from 1 to 5 instances for the various regions. Three 
of the 5 regions are known CNV regions; the events on chromosome 3 : 131.9 Mb are 
intragenic causing a deletion in CPNE4 (Supplementary Figure 2). The detected CNVs were 
small, ranging from 3.6–24.8 kb. The events contributing to the AAO association signals are 
detailed in Supplementary Table 3. The multivariate segmented data detected nominal 
associations only (data not shown); the number of events contributing to these signals were 
consistent with the segmentation method developed to detect common CNVs. The LOAD 
familial dataset probands were studied for replication of these signals (Supplementary Table 
2). The coverage of the candidate regions was limited on the Illumina 610 array 
(Supplementary Table 1) precluding conclusive interpretation of the replication study.
In order to further assess mutational load, the CNV load of the previously identified 10 
susceptibility loci [7] was evaluated in the TARCC dataset. CNVs that are overlapping with 
genes nearest to the reported associated SNPs are summarized in Table 3. We detected four 
small events in CR1 at two loci (Supplementary Figure 3) and two events in BIN1. In 
CD2AP, a small intragenic event was detected in a control.
DISCUSSION
Five CNV regions were detected with sizes ranging from 3.6–24.8 kb and allele frequencies 
of 0.001–0.006 suggesting that small events with low frequencies could contribute to the 
genetic architecture of AD. The previously reported [20] chromosome 14 olfactory receptor 
cluster association with AAO of AD was confirmed (uncorrected p-value of 0.03) in this 
analysis workflow, and the size of the effect is consistent with the smaller sample size (the 
reported association included a sample size of 507 subjects in contrast with the 375 reported 
here).
Published case-control CNV GWAS in AD applied a fundamentally different workflow by 
entering only high stringency calls typically in excess of 100 kb in size to the analyses. The 
CPNE4 deletion has been documented in the database of Genomic Variants (http://
projects.tcag.ca/variation/) and was validated in this set (Supplementary Figure 2). CPNE4 
encodes copine IV, a calcium-dependent membrane-binding protein highly expressed in the 
brain. The detected CNV events have a high probability supported by the consistent within 
event logR ratio values and their presence in the database of Genomic Variants (3 out of 5 
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loci). The limited availability of probes in the regions of interest in the Illumina Human 610 
or 650 arrays confounds the replication of these results in the NIA LOAD study, ADNI 
study, and the Caribbean Hispanic study, thus their significance remains unknown. Further 
larger replication studies with adequate coverage of the regions and molecular validation are 
needed. This emphasizes further challenges in CNV association studies: i) unlike SNPs 
single probe associations are usually not considered and several consecutive probes are 
needed to identify an event and ii) due to low allele frequencies, even larger studies are 
needed to have the power to detect the association than for SNP GWAS. Next generation 
whole genome sequencing evolved as a tool to detect most genetic variation in a single 
experiment; however, the cost and the large sample size needed in AD preclude their utility 
at this point in time.
Several small events overlapping genes in the 10 known susceptibility loci were identified 
suggesting that CNVs may contribute to the genetic architecture of these loci in AD. The 
CNV involving the CR1 gene at the low copy repeat region (Supplementary Figure 3, pink 
and blue bars) is consistent with previous reports and the direction of the CNV dosage in 
cases and controls consistent with the previously reported association [16]. Further work is 
needed to delineate the effect of these CNVs in AD.
Challenges to identifying the loci contributing to the heritability of AD are many fold. The 
disease affects the elderly, is common, and has an age-dependent penetrance, all 
contributing to misclassification bias which decreases power. The cases-only design 
attempts to eliminate the misclassification bias. Identification of genes that regulate AAO in 
AD may result in valid therapeutic targets as projections suggest that by postponing AAO by 
only 5 years may decrease the prevalence of AD by half [2]. CNVs are thought to contribute 
to the genetics of various diseases by intermediate frequency alleles with intermediate 
penetrance, which is confirmed in this study. Due to the lower allele frequencies compared 
to SNPs, CNV association studies need even larger sample sizes. Additional work is needed 
to validate and confirm these associations.
There have been several genome-wide scans involving over 10,000 cases and 10,000 
controls which have identified replicable loci [7]. However, these loci together account for 
only a small fraction of the heritability of AD [7]. In order to find the missing heritability, 
systematic assessment of structural variants, rare variants, DNA methylation, and common 
variants need to be performed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The Manhattan plot depicts the −log10p for the Cox proportional hazard regression using the 
array data (univariate segmentation covariates) as predictors and the age at onset (AAO) as 
outcome (n = 375). The chromosomes are shaded alternately and each segmentation 
covariate is represented by a dot.
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